Drug metabolism and personalized therapy最新文献

Predicting of factors associated with valsartan response among hypertensive patients attending the Jordan University Hospital.

Drug metabolism and personalized therapy Pub Date : 2025-02-06 DOI: 10.1515/dmpt-2024-0088

Shahd Khalil, Aseel Quran, Leen Thalji, Malk Al-Adamat, Lina Sabha, Joud Khraisat, Abdel Rahman Al Na'ami, Hatem Al-Jazzazi, Hussein Alhawari, Yazun Jarrar

{"title":"Predicting of factors associated with valsartan response among hypertensive patients attending the Jordan University Hospital.","authors":"Shahd Khalil, Aseel Quran, Leen Thalji, Malk Al-Adamat, Lina Sabha, Joud Khraisat, Abdel Rahman Al Na'ami, Hatem Al-Jazzazi, Hussein Alhawari, Yazun Jarrar","doi":"10.1515/dmpt-2024-0088","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0088","url":null,"abstract":"Objectives: There is an inter-individual in the valsartan response among hypertensive patients. However, clinical factors associated with this variation in the response is still not fully understood. The major purpose of this study is to predict the factors associated with valsartan response and their influence on decreasing blood pressure among patients.Methods: This study is a cross-sectional observational study. It included 91 hypertensive patients on valsartan treatment, selected through simple random sampling from the Jordan University Hospital. The clinical data was collected through documented medical records in the hospital's computerized system. The data was analyzed using the chi-square test to compare frequencies and categories.Results: Patients were divided into systolic and diastolic responders. No statistical significance was found between systolic response to valsartan's and gender, smoking, age, BMI, lipid profile and HbA1c status. Diastolic responders had a positive significance of p value = 0.006 with BMI categories, however there was no significance with any other factor.Conclusions: There was a better diastolic response to valsartan among hypertensive patients with lower BMI levels. BMI can be considered as a factor to personalize the therapy among patients on valsartan. However, further clinical studies with larger sample size are needed to confirm these data.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

'Pharmacogenetics, health and ethnicity in Latin American populations' call for the "Dr José María Cantú Award 2024". “拉丁美洲人口的药物遗传学、健康和种族”呼吁颁发“2024年jos<s:1>博士María Cantú奖”。

Drug metabolism and personalized therapy Pub Date : 2025-01-02 DOI: 10.1515/dmpt-2024-0091

José Elias Garcia-Ortiz, Ingrid Fricke, Humberto Fariñas, Alejandro Gaviño-Vergara, Alejandra Camacho-Molina, Marcela Gálvez, José Polo-García, Encarna Guillén-Navarro, Adrián Llerena Ruiz

引用次数: 0

'Pharmacogenetics, health and ethnicity in Latin American populations' call for the "Dr José María Cantú Award 2024". “拉丁美洲人口的药物遗传学、健康和种族”呼吁颁发“2024年jos<s:1>博士María Cantú奖”。

Drug metabolism and personalized therapy Pub Date : 2025-01-02 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0091

José Elias Garcia-Ortiz, Ingrid Fricke, Humberto Fariñas, Alejandro Gaviño-Vergara, Alejandra Camacho-Molina, Marcela Gálvez, José Polo-García, Encarna Guillén-Navarro, Adrián Llerena Ruiz

引用次数: 0

Molecular docking and in vitro evaluation of glucosamine sulfate targeting MMP-3, MMP-9, and IL-4 for potential osteoarthritis treatment. 靶向MMP-3、MMP-9和IL-4治疗骨关节炎的硫酸氨基葡萄糖分子对接及体外评价

Drug metabolism and personalized therapy Pub Date : 2024-12-19 DOI: 10.1515/dmpt-2024-0067

Venkataramanan Srinivasan, Selvaraj Kunjiappan, Ponnusamy Palanisamy

{"title":"Molecular docking and in vitro evaluation of glucosamine sulfate targeting MMP-3, MMP-9, and IL-4 for potential osteoarthritis treatment.","authors":"Venkataramanan Srinivasan, Selvaraj Kunjiappan, Ponnusamy Palanisamy","doi":"10.1515/dmpt-2024-0067","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0067","url":null,"abstract":"Objectives: This study intended to investigate the potential of glucosamine sulfate (GS) as an inhibitor of genes involved in osteoarthritis (OA) development. Despite GS is often used for OA treatment due to its cartilage preservation and minimum side effects, the molecular mechanism behind its interactions remains unknown.Methods: Molecular docking was conducted to analyze the interactions between glucosamine sulfate and genes associated with OA such as matrix metalloproteinase-3 (MMP-3), MMP-9, and interleukin-4 (IL-4). Additionally, a cell viability assay using RAW 264.7 cells was performed to evaluate the toxicity of glucosamine sulfate at various concentrations.Results: Molecular docking results revealed that glucosamine sulfate has a good binding affinity and stable interactions with MMP-3, MMP-9, and IL-4, indicating that it may have inhibitory effects on targeted genes. Nevertheless, the cell viability assay analysis demonstrated that glucosamine sulfate had considerable toxic effects in RAW 264.7 cells at highest concentrations.Conclusions: Glucosamine sulfate exhibited stable molecular interactions with genes associated to OA development. However, GS toxicity at high concentrations necessitates future research studies to optimize dosing and assess its therapeutic safety in OA treatment.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prolonged post-operative hydrocodone usage due to psychotropic drug interaction. 精神药物相互作用导致术后长期使用氢可酮。

Drug metabolism and personalized therapy Pub Date : 2024-12-16 DOI: 10.1515/dmpt-2024-0031

Aaron G Whitt, Viana F Karimi, Jeremy T Gaskins, Ruby E Renfrow, Abbey R Roach, Arthur L Malkani, Brandi Hartley, Madhusudhan R Yakkanti, Saeed A Jortani

{"title":"Prolonged post-operative hydrocodone usage due to psychotropic drug interaction.","authors":"Aaron G Whitt, Viana F Karimi, Jeremy T Gaskins, Ruby E Renfrow, Abbey R Roach, Arthur L Malkani, Brandi Hartley, Madhusudhan R Yakkanti, Saeed A Jortani","doi":"10.1515/dmpt-2024-0031","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0031","url":null,"abstract":"Objectives: To explore pain outcomes in patients prescribed hydrocodone and psychotropic medications with or without CYP2D6 inhibition activity.Methods: Patients hospitalized for lower/limited upper extremity injuries who were prescribed hydrocodone alongside a psychotropic medication were considered for this study (n=224). A subset of these patients (n=178) was prescribed a psychotropic medication known to inhibit CYP2D6, while the remainder (n=46) were prescribed psychotropic medications without CYP2D6 inhibition activity. Patient demographics and pain outcomes were collected by electronic health record review and interviews.Results: Patients taking a psychotropic inhibitor of CYP2D6 exhibited longer duration of opioid use post-discharge (median 33 days [IQR 10-99]) compared with patients taking a psychotropic non-inhibitor (4 days [2-20], p<0.001). No significant differences were observed with in-hospital pain outcomes, including total dose of hydrocodone administered, duration of hydrocodone use, pain index scores, and the occurrence of common mild/moderate/severe hydrocodone side effects.Conclusions: Patients prescribed at least one psychotropic inhibitor of CYP2D6 were more likely to continue using hydrocodone for up to 3 months following surgery. Knowledge of these critical drug-drug interactions could enhance clinical practice and improve patient outcomes. This study highlights negative post-operative pain outcomes in patients prescribed hydrocodone alongside a psychotropic inhibitor of CYP2D6. The results of this study indicate that patients taking psychotropic medications that inhibit CYP2D6 are at increased risk for prolonged hydrocodone use following orthopedic surgery.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing tacrolimus therapeutic drug monitoring in Tunisian kidney transplant recipients: exploring the variability in bioavailability and the correlation between pharmacokinetic parameters. 优化突尼斯肾移植受者他克莫司治疗药物监测：探索生物利用度的变异性和药代动力学参数之间的相关性。

Drug metabolism and personalized therapy Pub Date : 2024-12-16 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0043

Ghaith Aloui, Rym Charfi, Mouna Daldoul, Syrine Ben Hammamia, Mouna Ben Sassi, Mohamed Zouari, Hanene Eljeberi, Riadh Daghfous, Emna Gaies, Sameh Trabesli

{"title":"Optimizing tacrolimus therapeutic drug monitoring in Tunisian kidney transplant recipients: exploring the variability in bioavailability and the correlation between pharmacokinetic parameters.","authors":"Ghaith Aloui, Rym Charfi, Mouna Daldoul, Syrine Ben Hammamia, Mouna Ben Sassi, Mohamed Zouari, Hanene Eljeberi, Riadh Daghfous, Emna Gaies, Sameh Trabesli","doi":"10.1515/dmpt-2024-0043","DOIUrl":"10.1515/dmpt-2024-0043","url":null,"abstract":"Objectives: While the existing literature extensively covers the topic of tacrolimus variability, it remains crucial to gather data that are tailored to the Tunisian population. Our primary goal was to assess the variability in tacrolimus bioavailability using the Cp(0)/weight dosage ratio in Tunisian kidney transplant patients. We also aimed to determine the correlations between blood trough level (Cp(0)) and the area under the concentration-time curve (AUC0-12 h) in this cohort.Methods: This retrospective study included patients treated with oral tacrolimus for the prevention of organ rejection between 2009 and 2023. The correlation between parameters was analyzed through a Pearson coefficient and a regression model. We assessed the inter- and intraindividual variability by calculating the coefficient of variation for patients with at least three samples.Results: Analysis of 2,124 samples revealed a weak correlation (R=0.121) between Cp(0) and weight dosage. We found that 79.3 % of patients exhibited high variability in the Cp(0)/weight dosage ratio. A strong correlation (R=0.797) was found between Cp(0) and the AUC0-12 h. We also found that 47.6 % of patients showed high variability in the AUC0-12 h/Cp(0) ratio.Conclusions: This study underscores the necessity for individualized therapeutic drug monitoring in Tunisian kidney transplant recipients due to the high variability in the Cp(0)/weight dosage ratio. The AUC0-12 h/Cp(0) ratio is proposed as a more consistent parameter for therapeutic drug monitoring, offering potential improvements in tacrolimus therapy management.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"215-220"},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of metformin on exercise capacity in treatment naïve type 2 diabetes patients. 二甲双胍对初次接受治疗的 2 型糖尿病患者运动能力的影响。

Drug metabolism and personalized therapy Pub Date : 2024-12-16 DOI: 10.1515/dmpt-2024-0049

Vikneswaran Gunaseelan, Sandhiya Selvarajan, Sadishkumar Kamalanathan, Tamilarasu Kadhiravan, Shravan Venkatraman

{"title":"Effect of metformin on exercise capacity in treatment naïve type 2 diabetes patients.","authors":"Vikneswaran Gunaseelan, Sandhiya Selvarajan, Sadishkumar Kamalanathan, Tamilarasu Kadhiravan, Shravan Venkatraman","doi":"10.1515/dmpt-2024-0049","DOIUrl":"https://doi.org/10.1515/dmpt-2024-0049","url":null,"abstract":"Objectives: Exercise capacity is decreased in diabetes mellitus due to impaired insulin sensitivity, endothelial dysfunction and mitochondrial dysfunction. The aim of the study was to evaluate the effect of metformin on exercise capacity in treatment naïve patients with type 2 diabetes mellitus.Methods: Newly diagnosed type 2 diabetes mellitus patients were tested for baseline insulin resistance and exercise capacity, before starting on metformin. Exercise capacity was measured by incremental exercise testing in treadmill (ZAN 600 CPET system) using modified Bruce protocol at baseline, 6 weeks and 12 weeks following metformin therapy.Results: A total of 33 treatment naïve type 2 diabetes patients were enrolled of which 19 patients completed the study. There was no significant change in any of the exercise capacity parameters at the end of 12 weeks of metformin. Nevertheless, there was a significant improvement in VO2/kg among those with insulin resistance as compared to those without insulin resistance.Conclusions: Metformin monotherapy did not produce any change in exercise capacity in treatment naïve type 2 diabetes patients. However, a significant fall in exercise capacity (VO2/kg) was observed in patients without insulin resistance as compared to those with insulin resistance at the end of 12 weeks of metformin therapy.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CYP2C19 genotype-phenotype correlation: current insights and unanswered questions. CYP2C19基因型-表型相关性：目前的见解和尚未解决的问题。

Drug metabolism and personalized therapy Pub Date : 2024-12-13 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0093

Nadine de Godoy Torso, Fernanda Rodrigues-Soares, Catalina Altamirano, Ronald Ramírez-Roa, Martha Sosa-Macías, Carlos Galavíz-Hernández, Enrique Terán, Eva Peñas-LLedó, Pedro Dorado, Adrián LLerena

引用次数: 0

UHPLC-MS/MS standardized extract of Vernonia amygdalina leaf inhibits CYP2C9 and CYP3A4 activities in hepatic cells of control and streptozotocin-induced diabetic rats. 苦杏仁叶UHPLC-MS/MS标准提取物抑制链脲霉素诱导的糖尿病大鼠肝细胞CYP2C9和CYP3A4活性。

Drug metabolism and personalized therapy Pub Date : 2024-12-12 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0005

Bassel Al Sabbagh, Vijayaraj Kumar Palanirajan, Yik-Ling Chew, Jin Han Chin, Mariam Ahmad, Gabriel Akyirem Akowuah

{"title":"UHPLC-MS/MS standardized extract of Vernonia amygdalina leaf inhibits CYP2C9 and CYP3A4 activities in hepatic cells of control and streptozotocin-induced diabetic rats.","authors":"Bassel Al Sabbagh, Vijayaraj Kumar Palanirajan, Yik-Ling Chew, Jin Han Chin, Mariam Ahmad, Gabriel Akyirem Akowuah","doi":"10.1515/dmpt-2024-0005","DOIUrl":"10.1515/dmpt-2024-0005","url":null,"abstract":"Objectives: Vernonia amygdalina Del. is a perennial tropical shrub from Asteraceae. The fresh leaf of V. amygdalina is consumed as a vegetable due to its medicinal and nutritional properties. The present study focused on the quantification of bioactive compounds, luteolin-7-O-glucoside, luteolin-7-O-glucuronide, and 1,5-O-dicaffeoylquinic acid from aqueous leaf extract of V. amygdalina. The study also aims to investigate the effects of the aqueous leaf extract of V. amygdalina on cytochrome P450 2C9 (CYP2C9), and cytochrome P450 3A4 (CYP3A4) in hepatic cells of control and diabetic rats.Methods: The quantification of the bioactive compounds was conducted using ultra-high-performance liquid chromatography multiple reactions monitoring tandem mass spectrometry (UHPLC-MS/MS-MRM) technique. The effect of the extract on CYP2C9 and CYP3A4 activities was determined using a fluorometric screening kit according to the manufacturer's instructions.Results: The three bioactive compounds were detected and quantified in the aqueous leaf extract. Results showed that the content of luteolin-7-O-glucuronide (47 μg/mg) was the highest followed by luteolin-7-O-glucoside (3.5 μg/mg) and 1,5-O-dicaffeoylquinic acid (1.07 μg/mg). The extract showed an inhibitory effect on CYP3A4 and CYP2C9 enzyme activities in control and diabetic rats.Conclusions: The UHPLC-MS/MS-MRM method is sensitive and reliable for the quality control of V. amygdalina leaf extract. The inhibitory effect of the extract suggests that concomitant use of V. amygdalina leaf preparations with conventional drugs metabolized and eliminated from the body by CYP3A4 and CYP2C9 enzymes may lead to possible interaction.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"231-241"},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives. 西班牙在临床实践中实施药物遗传学的现状：从地区到国家的举措。

Drug metabolism and personalized therapy Pub Date : 2024-11-11 eCollection Date: 2024-12-01 DOI: 10.1515/dmpt-2024-0042

Maria Apellaniz-Ruiz, Jordi Barrachina, Paula Castro-Sanchez, Ana Comes-Raga, Xandra García-González, Almudena Gil-Rodriguez, Elixabet Lopez-Lopez, Olalla Maroñas, Rocío Morón, Javier Muriel, Gladys G Olivera, Pau Riera, Miriam Saiz-Rodríguez, Sara Salvador-Martín, Carla Sans-Pola, Hugo Tejera-Pérez, Alejandro Velasco-Ruiz, Zoraida Verde, Daniel Wang, Ana E Rodríguez-Vicente, Rocio Nunez-Torres

{"title":"Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives.","authors":"Maria Apellaniz-Ruiz, Jordi Barrachina, Paula Castro-Sanchez, Ana Comes-Raga, Xandra García-González, Almudena Gil-Rodriguez, Elixabet Lopez-Lopez, Olalla Maroñas, Rocío Morón, Javier Muriel, Gladys G Olivera, Pau Riera, Miriam Saiz-Rodríguez, Sara Salvador-Martín, Carla Sans-Pola, Hugo Tejera-Pérez, Alejandro Velasco-Ruiz, Zoraida Verde, Daniel Wang, Ana E Rodríguez-Vicente, Rocio Nunez-Torres","doi":"10.1515/dmpt-2024-0042","DOIUrl":"10.1515/dmpt-2024-0042","url":null,"abstract":"Introduction: Pharmacogenetics (PGx) has the potential to improve patient care, allowing to transform medical interventions by providing personalized therapeutic strategies. Scientific evidence supports the use of PGx in clinical practice and international organizations are developing clinical guidelines to facilitate the utilization of PGx testing. However, clinical implementation of PGx is limited and unequal worldwide.Content: This review summarizes regional and national Spanish initiatives to implement PGx in the clinical practice.Summary and outlook: Diverse strategies to implement PGx in healthcare are applied across countries or even in the different regions of a specific country. Such was the case of Spain, a European country with 17 Autonomous Regions and two Autonomous Cities, each one with capacity to manage their own healthcare systems. Nevertheless, during the past years, many initiatives and strategies have been launched in Spain to develop different aspects of PGx. Importantly, the National Healthcare System has approved a PGx testing catalogue. This review highlights the crucial work and efforts of scientific societies (like the Spanish Society of Pharmacogenetics and Pharmacogenomics), of experts in PGx, of healthcare providers and of governmental parties in the implementation of PGx to personalize patient therapy, focused in Spain.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"183-199"},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0